GlaxoSmithKline Plc (GSK)-Medical Equipment-Deals and Alliances Profile

GlaxoSmithKline Plc (GSK)-Medical Equipment-Deals and Alliances Profile


  • Products Id :- GDME4279D
  • |
  • Pages: 127
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respiratory, immuno-inflammation and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases. GSK's vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc (GSK)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

GlaxoSmithKline Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6

GlaxoSmithKline Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 7

GlaxoSmithKline Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8

GlaxoSmithKline Plc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9

GlaxoSmithKline Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10

GlaxoSmithKline Plc, Medical Equipment, Deal Details 13

Venture Financing 13

Progyny Raises Additional USD10 Million in Series B Financing 13

Progyny Raises Additional Funds through Venture Financing 13

ZappRx Raises USD5.6 Million in Series A Financing 14

HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 15

ZappRx Raises US$2 Million In Seed Financing 16

Health XL Raises Funds Through Venture Financing 17

HTG Molecular Diagnostics Raises US$7.5 Million In Series E Financing 18

SR One Plans To Invest In Biotechnology Company 19

IlluminOss Medical Raises US$28 Million In Series C Financing 19

Auxogyn Raises US$18 Million In Series B Financing 21

SpringLeaf Therapeutics Secures Additional US$4 Million In Series B Financing 22

High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 23

Partnerships 24

GlaxoSmithKline to Form Joint Venture with Verily Life Sciences 24

GlaxoSmithKline May Form Joint Venture with Qualcomm 25

Propeller Health Enters into R&D Agreement with GlaxoSmithKline 26

Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 26

Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 28

Feinstein Institute For Medical Research Enters Into Research Agreement With GSK, University of Pennsylvania And MIT 29

AB-Biotics Enters Into Co-Promotion Agreement With GlaxoSmithKline For Neurofarmagen 30

KineMed Enters Into Co-Development Agreement With GlaxoSmithKline 30

Epistem Holdings Enters Into Co-Development Agreement With GlaxoSmithKline 31

Siemens Healthcare Diagnostics Enters Into Co-Development Agreement With ViiV Healthcare 32

Abbott Labs Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals 33

Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals 34

Enigma Diagnostics Enters Into Co-Development Agreement With GlaxoSmithKline 35

Imperial College London, King's College London, University College London, Medical Research Council And GSK Form Joint Venture 35

Insulet Enters Into Distribution Agreement With GlaxoSmithKline 37

Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 38

Equity Offering 38

Response Genetics Completes Private Placement Of Shares For US$9 Million 38

Asset Transactions 39

Sinclair IS Pharma Acquires Atlean From Stiefel Labs 39

Acquisition 40

GlaxoSmithKline May Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD10.3 Billion 40

Teleflex Acquires Semprus BioSciences For Up To US$80 Million 41

GlaxoSmithKline Plc-Key Competitors 43

Key Employees 44

Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Recent Developments 59

Strategy And Business Planning 59

Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms 59

May 20, 2016: Avalon Ventures and COI Pharmaceuticals Announce First Milestones for Sitari Pharmaceuticals and Silarus Therapeutics and Formation of Eighth Company 60

Apr 18, 2016: GSK opens new state of the art respiratory manufacturing facility in Ware, UK 61

Apr 04, 2016: Heptares Joins Pharma Consortium Applying State of the Art Cryo-Electron Microscopy to Advance Structure Based Drug Discovery 62

Jan 25, 2016: AstraZeneca partners with peers and academia to establish translational research fund 63

Financial Announcements 64

Apr 26, 2017: GSK delivers another quarter of continued progress 64

Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016 67

Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016 83

Jul 27, 2016: GlaxoSmithKline: Results announcement for the second quarter 2016 and half-yearly financial report for the half-year 2016 89

Apr 27, 2016: GSK Announces First quarter 2016 103

Feb 03, 2016: GSK Announces Full year and Fourth Quarter 2015 Results 107

Corporate Communications 109

Jun 19, 2017: GSK confirms start date for Luke Miels 109

Apr 04, 2017: GSK responds to Cyclone Debbie 110

Jan 19, 2017: Abbas Hussain to leave GSK 111

Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK 112

Dec 19, 2016: GSK announces Board changes 113

Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare 114

Sep 20, 2016: Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline 115

Jul 07, 2016: GSK and Save the Children call for developing country innovations to enter $1 million award 116

Jun 14, 2016: GlaxoSmithKline: Executive Director Change 117

May 27, 2016: GlaxoSmithKline Announces Board and Committee changes 118

Mar 31, 2016: GSK expands graduated approach to patents and intellectual property to widen access to medicines in the world's poorest countries 119

Mar 17, 2016: Sir Andrew Witty to retire from GSK in March 2017 120

Mar 17, 2016: GlaxoSmithKline: Directorate changes 121

Mar 04, 2016: GSK names winners of 2015 Discovery Fast Track Challenge 122

Legal and Regulatory 123

Jan 20, 2016: Scientists Indicted For Allegedly Stealing Biopharmaceutical Trade Secrets 123

Product News 124

May 30, 2016: ImaBiotech to conduct Pilot Study with GSK to assess ImaBiotech's Multimaging Technology 124

Mar 07, 2016: New Health Outcomes Data Reinforce Role of Device Selection and Peak Inspiratory Flow Rate in Treatment of COPD Patients 125

Other Significant Developments 126

Jul 27, 2016: GSK announces significant new investment in UK manufacturing network 126

Appendix 127

Methodology 127

About GlobalData 127

Contact Us 127

Disclaimer 127

List of Figures

GlaxoSmithKline Plc, Medical Equipment, Deals by Type, 2011 to YTD 2017 1

GlaxoSmithKline Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 1

GlaxoSmithKline Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 1

GlaxoSmithKline Plc, Medical Equipment, Deals By Market, 2011 to YTD 2017 1

GlaxoSmithKline Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6

GlaxoSmithKline Plc, Medical Equipment, Deals by Type, 2011 to YTD 2017 7

GlaxoSmithKline Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8

GlaxoSmithKline Plc, Medical Equipment, Deals by Market, 2011 to YTD 2017 9

List of Tables

GlaxoSmithKline Plc, Medical Equipment, Key Facts, 2016 1

GlaxoSmithKline Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1

GlaxoSmithKline Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6

GlaxoSmithKline Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 7

GlaxoSmithKline Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8

GlaxoSmithKline Plc, Deals By Market, 2011 to YTD 2017 9

GlaxoSmithKline Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10

Progyny Raises Additional USD10 Million in Series B Financing 13

Progyny Raises Additional Funds through Venture Financing 13

ZappRx Raises USD5.6 Million in Series A Financing 14

HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 15

ZappRx Raises US$2 Million In Seed Financing 16

Health XL Raises Funds Through Venture Financing 17

HTG Molecular Diagnostics Raises US$7.5 Million In Series E Financing 18

SR One Plans To Invest In Biotechnology Company 19

IlluminOss Medical Raises US$28 Million In Series C Financing 19

Auxogyn Raises US$18 Million In Series B Financing 21

SpringLeaf Therapeutics Secures Additional US$4 Million In Series B Financing 22

High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 23

GlaxoSmithKline to Form Joint Venture with Verily Life Sciences 24

GlaxoSmithKline May Form Joint Venture with Qualcomm 25

Propeller Health Enters into R&D Agreement with GlaxoSmithKline 26

Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 26

Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 28

Feinstein Institute For Medical Research Enters Into Research Agreement With GSK, University of Pennsylvania And MIT 29

AB-Biotics Enters Into Co-Promotion Agreement With GlaxoSmithKline For Neurofarmagen 30

KineMed Enters Into Co-Development Agreement With GlaxoSmithKline 30

Epistem Holdings Enters Into Co-Development Agreement With GlaxoSmithKline 31

Siemens Healthcare Diagnostics Enters Into Co-Development Agreement With ViiV Healthcare 32

Abbott Labs Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals 33

Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals 34

Enigma Diagnostics Enters Into Co-Development Agreement With GlaxoSmithKline 35

Imperial College London, King's College London, University College London, Medical Research Council And GSK Form Joint Venture 35

Insulet Enters Into Distribution Agreement With GlaxoSmithKline 37

Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 38

Response Genetics Completes Private Placement Of Shares For US$9 Million 38

Sinclair IS Pharma Acquires Atlean From Stiefel Labs 39

GlaxoSmithKline May Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD10.3 Billion 40

Teleflex Acquires Semprus BioSciences For Up To US$80 Million 41

GlaxoSmithKline Plc, Key Competitors 43

GlaxoSmithKline Plc, Key Employees 44

GlaxoSmithKline Plc, Other Locations 45

GlaxoSmithKline Plc, Subsidiaries 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

GlaxoSmithKline Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16090
Site License
USD 500 INR 32180
Corporate User License
USD 750 INR 48270

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com